The genetic complexity and heterogeneity of gastric and GEJ adenocarcinoma poses a significant challenge for the development of treatment strategies for these cancers. Despite advancements in the treatment algorithm with the use of Keytruda (Merck & Co.) for metastatic gastric and GEJ adenocarcinoma tumors expressing PD-L1 and Herceptin (Roche/Genentech) for HER2-positive metastatic gastric or GEJ adenocarcinoma, therapeutic options for a large proportion of metastatic patients remain severely limited. Cyramza (Eli Lilly), with or without paclitaxel, is frequently prescribed for second- and subsequent-line treatment of metastatic gastric and GEJ adenocarcinoma. Cytotoxic monotherapies and doublet or triplet chemotherapy regimens remain a mainstay of treatment. The substantial unmet medical need for therapeutic management of metastatic gastric and GEJ adenocarcinoma with efficacious and well-tolerated novel therapies presents an attractive opportunity for drug developers.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom.
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in June 2018.
Key companies: Roche/Genentech, Eli Lilly, Merck & Co.
Key drugs: Herceptin, Cyramza, Keytruda.